PHENYLEPHRINE HYDROCHLORIDE- phenylephrine hydrochloride solution/ drops
Akorn, Inc.
Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.
----------
Phenylephrine Hydrochloride
Ophthalmic Solution, USP
WARNING: PHYSICIANS SHOULD COMPLETELY FAMILIARIZE THEMSELVES WITH THE COMPLETE CONTENTS OF THIS LEAFLET BEFORE PRESCRIBING PHENYLEPHRINE HYDROCHLORIDE OPHTHALMIC SOLUTION.
DESCRIPTION:
Phenylephrine Hydrochloride Ophthalmic Solution, USP is a vasoconstrictor and mydriatic for use in ophthalmology. Phenylephrine is a synthetic sympathomimetic compound structurally similar to epinephrine and ephedrine. Phenylephrine Hydrochloride Ophthalmic Solution is supplied as a sterile topical ophthalmic solution. The active ingredient, phenylephrine hydrochloride, is represented by the chemical structure:
C9H13NO2•HCl Molecular Weight 203.67
CLINICAL PHARMACOLOGY:
Phenylephrine Hydrochloride Ophthalmic Solution is an alpha receptor sympathetic agonist used in local ocular disorders because of its vasoconstrictor and mydriatic action. It exhibits rapid and moderately prolonged action, and it produces little rebound vasodilation. Systemic side effects are uncommon.
Although rare, systemic absorption of sufficient quantities of phenylephrine may lead to systemic α-adrenergic affects, such as a rise in blood pressure which may be accompanied by a reflex atropine-sensitive bradycardia.
INDICATIONS AND USAGE:
Phenylephrine Hydrochloride Ophthalmic Solution is recommended as a vasoconstrictor, decongestant, and mydriatic in a variety of ophthalmic conditions and procedures. Some of its uses are for pupillary dilation in uveitis (to prevent or aid in the disruption of posterior synechia formation), for many ophthalmic surgical procedures.
CONTRAINDICATIONS:
Ophthalmic solutions of phenylephrine hydrochloride are contraindicated in patients with anatomically narrow angles or narrow angle glaucoma. Phenylephrine hydrochloride is contraindicated in infants and in some elderly adults with severe arteriosclerotic cardiovascular or cerebrovascular disease. Phenylephrine hydrochloride may be contraindicated during intraocular operative procedures when the corneal epithelial barrier has been disturbed. This preparation is also contraindicated in persons with a known sensitivity to phenylephrine hydrochloride or any of its components.
WARNINGS:
Not for intraocular use. As with other adrenergic drugs, when Phenylephrine Hydrochloride Ophthalmic Solution is administered simultaneously with, or up to 21 days after, administration of monoamine oxidase (MAO) inhibitors, careful supervision and adjustment of dosages are required since exaggerated adrenergic effects may result. The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants. Systemic side effects are more common in patients taking beta adrenergic blocking agents such as propranolol. Concomitant use of phenylephrine and atropine may enhance the pressor effects and induce tachycardia in some patients, especially infants.1
There have been rare reports associating the use of phenylephrine hydrochloride 10% ophthalmic solutions with the development of serious cardiovascular reactions, including ventricular arrhythmias and myocardial infarctions. These episodes, some ending fatally, have usually occurred in elderly patients with preexisting cardiovascular diseases.
PRECAUTIONS:
General: Ordinarily, any mydriatic, including phenylephrine hydrochloride, is contraindicated in patients with glaucoma, since it may occasionally raise intraocular pressure. However, when temporary dilation of the pupil may free adhesions, this advantage may temporarily outweigh the danger from coincident dilation of the pupil. Rebound miosis has been reported in older persons one day after receiving phenylephrine hydrochloride ophthalmic solutions, and reinstillation of the drug may produce less mydriasis than previously. This may be of clinical importance in dilating the pupils of older subjects prior to retinal detachment or cataract surgery. The lacrimal sac should be compressed by digital pressure for two to three minutes after instillation to avoid excessive systemic absorption. Due to a strong action of the drug on the dilator muscle, older individuals may also develop transient pigment floaters in the aqueous humor 40 to 45 minutes following the administration of phenylephrine hydrochloride ophthalmic solution. The appearance may be similar to anterior uveitis or to a microscopic hyphema. To prevent pain, a drop of suitable topical anesthetic may be applied before using Phenylephrine Hydrochloride Ophthalmic Solution. Prolonged exposure to air or strong light may cause oxidation and discoloration. Monitor blood pressure in geriatric patients with known cardiac disease. Exceeding recommended dosages or applying Phenylephrine Hydrochloride Ophthalmic Solution to the instrumented, traumatized, diseased or postsurgical eye or adnexa, or to patients with suppressed lacrimation, as during anesthesia, may result in the absorption of sufficient quantities of phenylephrine to produce a systemic vasopressor response.
INFORMATION FOR PATIENTS: DO NOT TOUCH DROPPER TIP TO ANY SURFACE AS THIS MAY CONTAMINATE THE SOLUTION. DO NOT USE IF SOLUTION IS BROWN OR CONTAINS A PRECIPITATE.
Drug Interaction: As with all other adrenergic drugs, when Phenylephrine Hydrochloride Ophthalmic Solution is administered simultaneously with, or up to 21 days after, administration of monoamine oxidase (MAO) inhibitors, careful supervision and adjustment of dosages are required since exaggerated adrenergic effects may occur. The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants, propranolol, reserpine, guanethidine, methyldopa, and atropine-like drugs. Phenylephrine hydrochloride ophthalmic solutions may potentiate the cardiovascular depressant effects of potent inhalation anesthetic agents.
Carcinogenesis, Mutagenesis, Impairment of Fertility:
Carcinogenicity studies with phenylephrine hydrochloride have been completed in mice at doses up to 2500 ppm in feed and in rats at doses up to 1250 ppm in feed. Phenylephrine hydrochloride demonstrated no carcinogenic effect in male or female mice and rats.
Pregnancy: Pregnancy Category C. Animal reproduction studies have not been conducted with phenylephrine hydrochloride ophthalmic solution. It is also not known whether phenylephrine hydrochloride ophthalmic solution can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Phenylephrine Hydrochloride Ophthalmic Solution should be given to a pregnant woman only if clearly needed.
Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Phenylephrine Hydrochloride Ophthalmic Solution is administered to a nursing woman.
Pediatric Use: Phenylephrine Hydrochloride Ophthalmic Solution is contraindicated in pediatric patients.
Exceeding recommended dosages or applying Phenylephrine Hydrochloride Ophthalmic Solution to the instrumented, traumatized, diseased or post surgical eye or adnexa, or to patients with suppressed lacrimation, as during anesthesia, may result in the absorption of sufficient quantities of phenylephrine to produce a systemic vasopressor response.
The hypertensive effects of phenylephrine may be treated with an alpha-adrenergic blocking agent such as phentolamine mesylate, 5 mg to 10 mg intravenously, repeated as necessary.
The oral LD50 of phenylephrine in the rat: 350 mg/kg, in the mouse: 120 mg/kg.
ADVERSE REACTIONS:
A marked increase in blood pressure has been reported in low-weight premature neonates, infants and adult patients with idiopathic orthostatic hypotension. Cardiovascular reactions which have occurred primarily in elderly patients include marked increase in blood pressure, syncope, myocardial infarction, tachycardia, arrhythmia, and fatal subarachnoid hemorrhage.2
Other reactions include bradycardia, headache, and excitability.
DOSAGE AND ADMINISTRATION:
Vasoconstriction and Pupil Dilatation: Phenylephrine Hydrochloride Ophthalmic Solution is especially useful when rapid and powerful dilatation of the pupil without cycloplegia and reduction of congestion in the capillary bed are desired. A drop of a suitable topical anesthetic may be applied, followed in a few minutes by 1 drop of Phenylephrine Hydrochloride Ophthalmic Solution to the upper limbus. The anesthetic prevents stinging and consequent dilution of the solution by lacrimation. It may occasionally be necessary to repeat the instillation after one hour, again preceded by the use of the topical anesthetic.
Uveitis: Posterior Synechiae: Phenylephrine Hydrochloride Ophthalmic Solution may be used in patients with uveitis when synechiae are present or may develop. The formation of synechiae may be prevented by the use of this solution and atropine or other cycloplegics to produce wide dilatation of the pupil. It should be emphasized, however, that the vasoconstrictor effect of Phenylephrine Hydrochloride Ophthalmic Solution may be antagonistic to the increase of local blood flow in uveal infection.
To free recently formed posterior synechiae, one drop of Phenylephrine Hydrochloride Ophthalmic Solution may be applied to the upper surface of the cornea. On the following day, treatment may be continued if necessary. In the interim, hot compresses should be applied for five or ten minutes three times a day, with one drop of a 1% or 2% solution of atropine sulfate before and after each series of compresses.
Glaucoma: In certain patients with glaucoma, temporary reduction of intraocular tension may be attained by producing vasoconstriction of the intraocular vessels; this may be accomplished by placing 1 drop of Phenylephrine Hydrochloride Ophthalmic Solution on the upper surface of the cornea. This treatment may be repeated as often as necessary.
Phenylephrine Hydrochloride Ophthalmic Solution may be used with miotics in patients with wide angle glaucoma. It reduces the difficulties experienced by the patient because of the small field produced by miosis, and still it permits and often supports the effect of the miotic in lowering the intraocular pressure. Hence, there may be marked improvement in visual acuity after using Phenylephrine Hydrochloride Ophthalmic Solution in conjunction with miotic drugs.
HOW SUPPLIED:
Phenylephrine Hydrochloride Ophthalmic Solution, USP is supplied as a sterile solution in plastic dropper bottles in the following sizes:
2 mL-NDC 17478-205-20
5 mL-NDC 17478-205-10
REFERENCES:
- Fraunfelder, F.T., and Meyer, S.M.: Possible Cardiovascular Effects Secondary to Topical Ophthalmic 2.5% Phenylephrine, Am. J. Oph. 99:3:362, 1985.
- Ibid.
Akorn
Manufactured by: Akorn, Inc.
Lake Forest, IL 60045
DLB0N
Rev. 07/11
| PHENYLEPHRINE HYDROCHLORIDE
phenylephrine hydrochloride solution/ drops |
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Labeler - Akorn, Inc. (062649876) |
| Establishment | |||
| Name | Address | ID/FEI | Business Operations |
|---|---|---|---|
| Akorn, Inc. | 155135783 | MANUFACTURE(17478-205), REPACK(17478-205), ANALYSIS(17478-205) | |